Literature DB >> 27784603

Surgical Treatment of Erectile Dysfunction.

Eduardo B Bertero1, Dimas L Antunes2.   

Abstract

INTRODUCTION: Currently, oral pharmacotherapy is the dominant treatment for erectile dysfunction. AIM: The aim of this article is to give an up-to-date summary of the possibilities of surgical therapy.
METHODS: A search of the literature over the last decade was performed. Relevant papers and guidelines on the topic were reviewed and included. MAIN OUTCOME MEASURE: We evaluate therapy options, such as penile vein surgery, arterial revascularization, and penile prosthetics.
RESULTS: Vein surgery has faded into total insignificance due to the efficiency of oral and intracavernous therapeutics, and because of the known pathophysiology of corporal veno-occlusive dysfunction and the disappointing long-term results published in the literature. Penile revascularization surgery is performed today only in very limited number of patients with strict selection criteria such as age and exclusion of vascular risk factors.
CONCLUSIONS: Penile prosthetics is the only surgical therapy option maintaining its significance as a cure for erectile dysfunction. There are convincing long-term results with a high degree of patient and partner satisfaction, high patient acceptance, and a good functional durability of the mostly three-piece inflatable devices. Bertero EB and Antunes DL. Surgical treatment of erectile dysfunction.
Copyright © 2015 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Erectile Dysfunction Treatment; Impotence; Penile Implants; Penile Prosthesis; Vascular Surgical Procedures; Vasculogenic Erectile Dysfunction

Year:  2015        PMID: 27784603     DOI: 10.1002/smrj.60

Source DB:  PubMed          Journal:  Sex Med Rev        ISSN: 2050-0521


  1 in total

1.  Satisfaction assessment with malleable prosthetic implant of Spectra (AMS) and Genesis (Coloplast) models.

Authors:  A R Casabé; N Sarotto; C Gutierrez; A J Bechara
Journal:  Int J Impot Res       Date:  2016-08-25       Impact factor: 2.896

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.